Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Der Anaesthesist 48 (1999), S. 794-801 
    ISSN: 1432-055X
    Keywords: Schlüsselwörter Langzeitsedierung ; Closed-loop Steuerung ; EEG Medianfrequenz ; Pharmakokinetik ; Propofol ; Alfentanil ; Key words Long-term ICU sedation ; Closed-loop feedback control ; EEG median frequency ; Pharmacokinetics ; Propofol ; Alfentanil
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Abstract Objective: The primary aim of this study was to find out whether adequate long-term sedation (≥72 h) can be achieved in critically ill patients with an EEG median frequency controlled closed-loop system for the application of propofol 1% and 2%. Moreover, we investigated the pharmacokinetics and pharmacodynamics of propofol with respect to possible tolerance and compared the quality of sedation of both propofol formulations and their lipid load. Patients and methods: After institutional approval and written consent, 16 ASA II-IV patients were included in this study. Main inclusion criterion was the necessity for prolonged sedation/analgesia for at least 72 h. Sedation was induced and maintained using continuous infusion of propofol 1% (n=7) or 2% (n=9). Analgesia was maintained with continuous infusion of alfentanil. The EEG was recorded from four leads (Fp1,2 and C3,4) and the EEG median frequency was obtained from the power spectrum (0.5–32 Hz). Propofol was administered computer-controlled with a median frequency setpoint depending on the depth of sedation which was assessed clinically using a modified Ramsay score. Alfentanil was applied as TCI. Arterial plasma concentrations were measured by HPLC (propofol) and RIA (alfentanil). Pharmacokinetics of propofol and alfentanil were derived using a three compartment model. Results: All patients were successfully sedated for 77±9 h. The median EEG frequency during sedation was stable at 1.5±0.2 Hz. The sedation score increased from 1 in the first 12 h to values between 2 and 3 for the remaining sedation period. At the same time, propofol plasma concentrations increased from 0.7±0.3 µg/ml to 1.8±1.3 µg/ml. The patients required an average of 2.5 mg/kg/h propofol and 0.030 mg/kg/h alfentanil. Pharmacokinetics of propofol 2% showed an increased volume of distribution when compared to propofol 1%. Alfentanil clearance was found to be reduced with four patients having extremely small clearance values (33±3 ml/min). Triglyceride values increased up to 4.5±1.2 mmol/l for patients receiving propofol 1% and remained within normal range for propofol 2%. Conclusions: The EEG median frequency can be used for closed-loop control of propofol even for long-term sedation in critically ill patients. EEG median frequencies were similarly low as in deeply anaesthetised patients. No differences in quality of sedation were seen between the two propofol formulations, but propofol 2% seems to be advantageous due to lower lipid load and triglyceride values. Increasing concentrations of propofol at unchanged sedation scores and EEG median frequencies may indicate development of tolerance.
    Notes: Zusammenfassung Fragestellung: Bei 16 beatmungspflichtigen Intensivpatienten wurde die Praktikabilität einer EEG-gesteuerten closed-loop Sedierung mit Propofol über 72 h untersucht, die 1%- und 2%ige Emulsion hinsichtlich Sedierungsqualität, Fettbelastung und Toleranzentwicklung verglichen sowie die Pharmakokinetik von Propofol und Alfentanil bestimmt. Methodik: Die EEG-Medianfrequenz diente zur closed-loop Steuerung von Propofol, die Zielfrequenz richtete sich nach der klinisch (modifizierte Ramsayskala) beurteilten Sedierungstiefe. Alfentanil wurde als TCI appliziert. Arterielle Blutproben wurden zur Konzentrationsbestimmung entnommen. Ergebnisse: Alle Patienten waren mit einer Zielfrequenz von 1,5±0,2 Hz ausreichend sediert. Der Propofol- und Alfentanilverbrauch betrug 2,5 bzw. 0,030 mg/kg/h. Der Sedierungsscore stieg von 1 während der ersten 12 h auf 2 bis 3, die Propofolkonzentration von 0,7±0,3 µg/ml auf 1,8±1,3 µg/ml an. Propofol 2% zeigte größere Verteilungsvolumina als Propofol 1%. Vier Patienten hatten eine extrem kleine Alfentanilclearance. Die Triglyceridwerte waren für Propofol 1% erhöht. Schlußfolgerungen: EEG-closed-loop-Steuerung erlaubt eine adäquate Langzeitsedierung bei ähnlich tiefen Medianfrequenzen wie unter Narkose. Toleranzentwicklung auf Propofol scheint möglich. Die Fettbelastung ist unter Propofol 2% geringer.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1238
    Keywords: Intensive care ; Sedation ; Anaesthetics, intravenous ; Propofol ; Analgesia ; Alfentanil ; Pharmacokinetics ; Pharmacodynamics
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Objective Population pharmacokinetic analysis and pharmacodynamic profile of propofol/alfentanil infusions for sedation and analgesia of intensive care unit patients for up to 24 h. Design Institutional Review Board-approved prospective clinical trial. Setting The ten-bed intensive care unit of an university hospital. Patients 18 consecutive patients (ten men/eight women; age: 17–73 years, mean 51.6±16.7 years, SD; body weight: 60–110 kg, meand 82.9±11.2 kg. SD) requiring mechanical ventilation and prolonged sedation/analgesia after major surgery or trauma. Interventions Plasma propofol and alfentanil concentrations were measured at regular intervals during the long-term drug infusion using a high-performance liquid chromatography (propofol) and radioimmunoassay (alfentanil) analysis. The depth of sedation was controlled by monitoring a two-lead online EEG. Thus, drug application was computer controlled via a closed-loop EEG median-frequency feedback system. Results ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2±5.3 l; steady-state distribution volume (Vdss): 499±173 l; total clearance (Cltot): 1001−±150 ml/min; redistribution half-life (t1/2γ): 90±23 min; elimination half-life (t1/2β): 558±218 minutes. For alfentanil: V1: 31.9±10.1 l; Vdss: 124±41 l; Cltot: 345±70 ml/min; t1/2γ: 36±15 min; t1/2β: 275±94 min, respectively. Conclusions The population pharmacokinetic analysis of propofol/alfentanil for ICU sedation therapy revealed increased volumes of drug distribution and decreased elimination characteristics as compared to pharmacokinetic data from short-term infusions in surgical patients. This can be attributed in part to altered distribution/redistribution processes and/or drug elimination under the condition of ICU therapy. No significant drug accumulation was observed. For future long-term sedation and analgesia of ICU patients with propofol/alfentanil, this altered pharmacokinetic behaviour should be taken into consideration to allow a more individualized and safer dosing of this drug combination.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...